Brequinar and dipyridamole in combination exhibits synergistic antiviral activity against SARS-CoV-2 in vitro: Rationale for a host-acting antiviral treatment strategy for COVID-19

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19) and the associated global pandemic resulting in >400 million infections worldwide and several million deaths. The continued evolution of SARS-CoV-2 to potentially evade v...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Antiviral research 2022-10, Vol.206, p.105403-105403, Article 105403
Hauptverfasser:	Demarest, James F, Kienle, Maryline, Boytz, RuthMabel, Ayres, Mary, Kim, Eun Jung, Patten, J J, Chung, Donghoon, Gandhi, Varsha, Davey, Robert A, Sykes, David B, Shohdy, Nadim, Pottage, Jr, John C, Kumar, Vikram S
Format:	Artikel
Sprache:	eng
Schlagworte:	Antiviral Agents - pharmacology Antiviral Agents - therapeutic use Biphenyl Compounds COVID-19 Drug Treatment Dipyridamole - pharmacology Humans Quinaldines RNA Viruses SARS-CoV-2 Virus Replication
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!